[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to Buy from Neutral, raising its price target to $65 from $46. Analyst Michael Yee noted a severely skewed risk/reward ratio to the potential in the latter half of 2026, with […]",
    "url": "https://finnhub.io/api/news?id=d4da844c9249f604bf238c25b1040906b70ebad25e1c2971cfd2aa404256cb12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768938342,
      "headline": "Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock",
      "id": 138189556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to Buy from Neutral, raising its price target to $65 from $46. Analyst Michael Yee noted a severely skewed risk/reward ratio to the potential in the latter half of 2026, with […]",
      "url": "https://finnhub.io/api/news?id=d4da844c9249f604bf238c25b1040906b70ebad25e1c2971cfd2aa404256cb12"
    }
  },
  {
    "ts": null,
    "headline": "BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?",
    "summary": "Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious",
    "url": "https://finnhub.io/api/news?id=84ee9e70508ee969a7a76bf7a93f71e71e10b07d946912fb3f0f80d3ac6cc52b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768934460,
      "headline": "BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?",
      "id": 138189557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious",
      "url": "https://finnhub.io/api/news?id=84ee9e70508ee969a7a76bf7a93f71e71e10b07d946912fb3f0f80d3ac6cc52b"
    }
  },
  {
    "ts": null,
    "headline": "Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035",
    "summary": "Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and inf",
    "url": "https://finnhub.io/api/news?id=5960229961f93600ddb4e95f8f91c68bc93db807a2ba67217e43e17b7fb389c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768931700,
      "headline": "Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035",
      "id": 138188573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and inf",
      "url": "https://finnhub.io/api/news?id=5960229961f93600ddb4e95f8f91c68bc93db807a2ba67217e43e17b7fb389c6"
    }
  },
  {
    "ts": null,
    "headline": "Profit Alert: Netflix Goes All-Cash, Microsoft Cracks Healthcare AI, and How You Win",
    "summary": "Tuesday morning brings five major stories, and five ways to profit. Here’s what happened and how you make money from it. 1. Netflix Goes All-Cash: Warner Bros Deal Gets Real Netflix revised its Warner Bros. Discovery bid to $83 billion all-cash, ditching the cash-and-stock structure. The move simplifies shareholder approval and signals Netflix means business: ... Profit Alert: Netflix Goes All-Cash, Microsoft Cracks Healthcare AI, and How You Win",
    "url": "https://finnhub.io/api/news?id=b9bc3e5c7fb2153a1060d937a3a0e97c1cd61b2f7553646dd696e884fd3afd59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768917498,
      "headline": "Profit Alert: Netflix Goes All-Cash, Microsoft Cracks Healthcare AI, and How You Win",
      "id": 138187356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Tuesday morning brings five major stories, and five ways to profit. Here’s what happened and how you make money from it. 1. Netflix Goes All-Cash: Warner Bros Deal Gets Real Netflix revised its Warner Bros. Discovery bid to $83 billion all-cash, ditching the cash-and-stock structure. The move simplifies shareholder approval and signals Netflix means business: ... Profit Alert: Netflix Goes All-Cash, Microsoft Cracks Healthcare AI, and How You Win",
      "url": "https://finnhub.io/api/news?id=b9bc3e5c7fb2153a1060d937a3a0e97c1cd61b2f7553646dd696e884fd3afd59"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers partners with Microsoft for AI-driven lung cancer detection",
    "summary": "Jan 20 () - Bristol Myers Squibb said on Tuesday it had signed an agreement with Microsoft to ​use the tech company's AI-enabled radiology platform to ‌help speed up early detection of lung cancer. The collaboration will deploy U.",
    "url": "https://finnhub.io/api/news?id=ffb8fcfdedfea988a44d597e3ff091d40b008c012d7e81a4e2d10c55217cf15c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768914666,
      "headline": "Bristol Myers partners with Microsoft for AI-driven lung cancer detection",
      "id": 138186349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Jan 20 () - Bristol Myers Squibb said on Tuesday it had signed an agreement with Microsoft to ​use the tech company's AI-enabled radiology platform to ‌help speed up early detection of lung cancer. The collaboration will deploy U.",
      "url": "https://finnhub.io/api/news?id=ffb8fcfdedfea988a44d597e3ff091d40b008c012d7e81a4e2d10c55217cf15c"
    }
  },
  {
    "ts": null,
    "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
    "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.",
    "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911513,
      "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
      "id": 138188129,
      "image": "https://image.cnbcfm.com/api/v1/image/108244385-1766176930135-gettyimages-2252075211-TRUMP_DRUG_PRICING.jpeg?v=1766176955&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs. ",
      "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
    "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
    "url": "https://finnhub.io/api/news?id=ed09b44ab08f281a4de088cbafeaab49cefc834f8df46627d296be0c707030c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911000,
      "headline": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
      "id": 138186420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
      "url": "https://finnhub.io/api/news?id=ed09b44ab08f281a4de088cbafeaab49cefc834f8df46627d296be0c707030c5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
    "summary": "PRINCETON, N.J., January 20, 2026--Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
    "url": "https://finnhub.io/api/news?id=a9606fbf184c8960bc0ab36e646714fec65851ec2b1219b699483d18ba73d10b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768910340,
      "headline": "Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
      "id": 138186354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., January 20, 2026--Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
      "url": "https://finnhub.io/api/news?id=a9606fbf184c8960bc0ab36e646714fec65851ec2b1219b699483d18ba73d10b"
    }
  },
  {
    "ts": null,
    "headline": "Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026",
    "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company is placed second among the best cancer stocks on our list. TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the […]",
    "url": "https://finnhub.io/api/news?id=334f686e58bba942e6c3d3f04a993a9c638f84580f9fa4fb433ec474ec038da5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768903026,
      "headline": "Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026",
      "id": 138185054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company is placed second among the best cancer stocks on our list. TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the […]",
      "url": "https://finnhub.io/api/news?id=334f686e58bba942e6c3d3f04a993a9c638f84580f9fa4fb433ec474ec038da5"
    }
  }
]